Skip to main content
David Chien, MD, Nuclear Medicine, Westlake Village, CA

David Chien MD


Senior Vice President at Krystal Biotech

Join to view full profile
  • David Chien M.D.Westlake Village, CA 91362

Dr. Chien is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • * https://www.linkedin.com/in/davidchienmd/ * https://www.krystalbio.com/about-us/leaders/

Education & Training

  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineFellowship, PET/CT, 2010 - 2011
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Nuclear Medicine, 2007 - 2010
  • New York-Presbyterian/Queens
    New York-Presbyterian/QueensInternship, Internal Medicine, 2006 - 2007
  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 2006

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2027
  • NY State Medical License
    NY State Medical License 2010 - 2012
  • PA State Medical License
    PA State Medical License 2010 - 2012
  • Nuclear Medicine
    American Board of Nuclear Medicine Nuclear Medicine
  • Nuclear Cardiology
    Certification Board of Nuclear CardiologyNuclear Cardiology

Awards, Honors, & Recognition

  • National Research Service Award NIH, 2010
  • Young Investigator Award Society of Nuclear Medicine, 2009
  • Morton Levitt Research Award University of California Davis, 2004

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase 1 preliminary safety, efficacy, and biomarker data from venetoclax (ABT-199/GDC-0199) + bendamustine and rituximab in R/R non-Hodgkin’s lymphoma
    de Vos S, Swinnen L, Kozloff M, Wang D, Reid E, Nastoupil L, Fowler N, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Agarwal S, Ross J, Punnoose E, McKeegan E, Hei..., Hematol Oncol, 1/1/2015
  • A dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin’s lymphoma
    de Vos S, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D’Amico D, Dunbar M, Zhu M, Salem A, Heitner-Enschede S, Ricker JL, Chien D, Humerickho..., Haematologica, 1/1/2015
  • Hypoxia [18F] HX4 PET imaging in patients with head and neck cancer: repeatability and stability during radiotherapy
    Zegers C, Van Elmpt W, Hoebers F, Chien D, Lambini P, Radiotherapy and Oncology, 1/1/2015

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: